JP2009511450A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009511450A5 JP2009511450A5 JP2008534023A JP2008534023A JP2009511450A5 JP 2009511450 A5 JP2009511450 A5 JP 2009511450A5 JP 2008534023 A JP2008534023 A JP 2008534023A JP 2008534023 A JP2008534023 A JP 2008534023A JP 2009511450 A5 JP2009511450 A5 JP 2009511450A5
- Authority
- JP
- Japan
- Prior art keywords
- leukemia
- methyl
- formula
- pharmaceutical combination
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 4
- 229940124226 Farnesyltransferase inhibitor Drugs 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000032839 leukemia Diseases 0.000 claims 4
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 claims 4
- PLHJCIYEEKOWNM-HHHXNRCGSA-N tipifarnib Chemical compound CN1C=NC=C1[C@](N)(C=1C=C2C(C=3C=C(Cl)C=CC=3)=CC(=O)N(C)C2=CC=1)C1=CC=C(Cl)C=C1 PLHJCIYEEKOWNM-HHHXNRCGSA-N 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- DHMTURDWPRKSOA-RUZDIDTESA-N lonafarnib Chemical compound C1CN(C(=O)N)CCC1CC(=O)N1CCC([C@@H]2C3=C(Br)C=C(Cl)C=C3CCC3=CC(Br)=CN=C32)CC1 DHMTURDWPRKSOA-RUZDIDTESA-N 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- -1 4-methyl-1H-imidazol-1-yl Chemical group 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 238000011260 co-administration Methods 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72459405P | 2005-10-07 | 2005-10-07 | |
| PCT/EP2006/067117 WO2007042465A2 (en) | 2005-10-07 | 2006-10-05 | Combinati0n of nilotinib with farnesyl transferase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009511450A JP2009511450A (ja) | 2009-03-19 |
| JP2009511450A5 true JP2009511450A5 (enExample) | 2009-09-17 |
Family
ID=37943163
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008534023A Pending JP2009511450A (ja) | 2005-10-07 | 2006-10-05 | ニロチニブとファルネシルトランスフェラーゼ阻害剤の組合せ |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US20080255171A1 (enExample) |
| JP (1) | JP2009511450A (enExample) |
| WO (1) | WO2007042465A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2008012728A (es) * | 2006-04-05 | 2008-10-14 | Novartis Ag | Combinaciones de agentes terapeuticos para el tratamiento de cancer. |
| WO2009151683A2 (en) | 2008-03-12 | 2009-12-17 | Link Medicine Corporation | Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications |
| EP2358370A2 (en) * | 2008-11-13 | 2011-08-24 | Link Medicine Corporation | Treatment of proteinopathies using a farnesyl transferase inhibitor |
| AU2009313927A1 (en) | 2008-11-13 | 2010-05-20 | Astrazeneca Ab | Azaquinolinone derivatives and uses thereof |
| US20170368038A1 (en) * | 2014-12-18 | 2017-12-28 | Novartis Ag | Azabicyclooctane derivatives as fxr agonists for use in the treatment of liver and gastrointestinal diseases |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002028409A2 (en) * | 2000-10-05 | 2002-04-11 | Whitehead Institute For Biomedical Research | Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors |
| CN1479630A (zh) * | 2000-10-05 | 2004-03-03 | Q | 诱导癌细胞死亡和肿瘤消退的方法 |
| CN101181269A (zh) * | 2001-11-30 | 2008-05-21 | 先灵公司 | 法尼基蛋白转移酶抑制剂和其它抗肿瘤剂联合使用在制备抗癌症的药物中的应用 |
| GB0215676D0 (en) * | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
-
2006
- 2006-10-05 US US12/089,317 patent/US20080255171A1/en not_active Abandoned
- 2006-10-05 WO PCT/EP2006/067117 patent/WO2007042465A2/en not_active Ceased
- 2006-10-05 JP JP2008534023A patent/JP2009511450A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013531028A5 (enExample) | ||
| JP2009532438A5 (enExample) | ||
| JP2006523216A5 (enExample) | ||
| JP2017528507A5 (enExample) | ||
| JP2013523733A5 (enExample) | ||
| JP2017505293A5 (enExample) | ||
| JP2010515715A5 (enExample) | ||
| JP2014502641A5 (enExample) | ||
| JP2010525056A5 (enExample) | ||
| JP2020512337A5 (enExample) | ||
| JP2009511450A5 (enExample) | ||
| RU2008143703A (ru) | ПРИМЕНЕНИЕ ИНГИБИТОРОВ c-Src В КОМБИНАЦИИ С ПИРИМИДИЛАМИНОБЕНЗАМИДОМ ДЛЯ ЛЕЧЕНИЯ ЛЕЙКОЗА | |
| JP2009511568A5 (enExample) | ||
| NZ590839A (en) | Treatment of pulmonary arterial hypertension | |
| JP2012507535A5 (enExample) | ||
| JPWO2020175629A5 (enExample) | ||
| JP2013506674A5 (enExample) | ||
| CN115315423A (zh) | 取代芳基类化合物 | |
| JP2014528464A5 (enExample) | ||
| JP2008536853A5 (enExample) | ||
| JP2008519049A5 (enExample) | ||
| JP2005532397A5 (enExample) | ||
| JP2020500868A5 (enExample) | ||
| JP2019501134A5 (enExample) | ||
| JP2013544794A5 (enExample) |